In Silico welcomes new partnerships and collaborators for both sponsorship and educational purposes. For further details on the available possibilities, please send an email to board@sa-insilico.nl
____________________________________________________________________________
In Silico is currently partnering with the Utrecht Bioinformatics Center. The Utrecht Bioinformatics Center performs Life Science research using big data analysis on DNA, genes, proteins and cells. By integrating data from various sources, they develop innovative methods that address important problems in the whole complexity of the Life Sciences, such as cancer genomics, molecular evolution or plant-microbe interactions. The UBC fosters and promotes the bioinformatics community at the Utrecht Science Park.
____________________________________________________________________________
GenDx is specialized in molecular transplant diagnostics. Their team develops and offers excellent analysis software, a comprehensive line of reagents, services and education. These products are used by hospitals and diagnostics labs all over the world to find the best donor-recipient match and to monitor transplant success.
Do you also want to contribute to the quality of life and survival of transplant patients? GenDx frequently offers internships focused on Bioinformatics and/or Software Development. For more info, head over to their Careers page to get in touch with their HR team.
____________________________________________________________________________
Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow them on LinkedIn and X.
____________________________________________________________________________